Sanofi (EPA:SAN) Share Price Passes Above 200 Day Moving Average – Here’s Why

Shares of Sanofi (EPA:SAN) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of €77.95 and traded as high as €80.16. Sanofi shares last traded at €79.38, with a volume of 1,943,037 shares traded.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported second-quarter sales growth of 17.8% at constant exchange rates, exceeding expectations, and raised its 2026 sales-growth outlook to approximately 10%. Business earnings also beat estimates, supported by Dupixent and newer product launches. Sanofi boosts 2026 outlook after strong Q2 driven by Dupixent and new launches
• Positive Sentiment: Dupixent sales increased 37.6% and surpassed €5 billion for the first time in a quarter, reinforcing the drug’s role as Sanofi’s primary growth engine. Sanofi lifts 2026 outlook as dupilumab tops €5bn
• Neutral Sentiment: New CEO Paul Hudson’s successor, Thomas Garijo, is reviewing Sanofi’s late-stage pipeline and promising more disciplined research-and-development decisions. The review could improve capital allocation, but it also signals further changes may be ahead. New CEO Garijo sketches out vision to reverse Sanofi’s fortunes
• Negative Sentiment: Investors reacted negatively to pipeline setbacks, including Sanofi’s decision not to advance amlitelimab toward global regulatory submission and the discontinuation of itepekimab and balinatunfib programs. These cuts raise concerns about future growth beyond Dupixent. Sanofi Slides After Q2 as Investors Focus on Pipeline Cuts
• Negative Sentiment: Reported IFRS net income fell sharply to €343 million, with IFRS earnings per share of €0.29, making the headline earnings picture less robust despite stronger business EPS. The termination of a real-world Dupilumab study in chronic urticaria adds another development-related uncertainty, although it does not appear to threaten current Dupixent sales. Regeneron and Sanofi Terminate Real-World Dupilumab Study

Sanofi Price Performance

The stock has a 50-day moving average of €75.86 and a 200-day moving average of €77.93.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines.